Cerus Corporation CERS

Company Overview

Cerus Corporation is a biomedical products company focused on developing and commercializing pathogen reduction technologies designed to enhance the safety of the global blood supply. The company operates within the biotechnology and medical devices industries, with a specific emphasis on transfusion medicine and blood safety. Cerus’s core offering is the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens in blood components.

The company primarily generates revenue through the sale of disposable kits, illuminators, and related services associated with the INTERCEPT Blood System for platelets and plasma, with development activities ongoing for red blood cells. Cerus serves blood centers, hospitals, and national blood services, with a strong strategic position driven by regulatory approvals, long-term supply agreements, and increasing regulatory focus on blood safety. Founded in 1991, Cerus evolved from a research-oriented biotechnology firm into a commercial-stage company following regulatory approvals in Europe and later the United States, significantly expanding its market reach over the past decade.